Physicochemical Properties
| Molecular Formula | C19H22O9 |
| Molecular Weight | 394.3726 |
| Exact Mass | 394.126 |
| Elemental Analysis | C, 57.87; H, 5.62; O, 36.51 |
| CAS # | 30861-27-9 |
| Related CAS # | 30861-27-9 |
| PubChem CID | 160190 |
| Appearance | White to off-white solid powder |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 628.0±55.0 °C at 760 mmHg |
| Flash Point | 224.2±25.0 °C |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.637 |
| LogP | 0.64 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 28 |
| Complexity | 647 |
| Defined Atom Stereocenter Count | 5 |
| SMILES | O1[C@]([H])(C([H])([H])O[H])[C@]([H])([C@@]([H])([C@]([H])([C@]1([H])C1=C(C([H])=C(C([H])([H])[H])C2C(C([H])=C(C([H])([H])C(C([H])([H])[H])=O)OC1=2)=O)O[H])O[H])O[H])O[H] |
| InChi Key | HKIKAXXIWJHWLY-ZIIYPAMZSA-N |
| InChi Code | InChI=1S/C19H22O9/c1-7-3-10(22)14(19-17(26)16(25)15(24)12(6-20)28-19)18-13(7)11(23)5-9(27-18)4-8(2)21/h3,5,12,15-17,19-20,22,24-26H,4,6H2,1-2H3/t12-,15-,16+,17-,19+/m1/s1 |
| Chemical Name | 7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one |
| Synonyms | Aloesin; Aloeresin B; Aloe resin B |
| HS Tariff Code | 2934.99.03.00 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro |
Aloesin (0-40 μM, 24, 48, and 72 h) inhibits the growth of ovarian cancer cells in a time- and dose-dependent way[1]. Aloesin (0-10 μM; 48 h) dose-dependently arrests the cell cycle at S-phase in SKOV3 cells[1]. Aloesin (0-10 μM; 48 h) induces cell death in SKOV3 cells[1]. Aloesin (0-10 μM; 48 h) prevents the MAPK signaling pathway from becoming phosphorylated[1]. |
| ln Vivo | Aloesin (injection; 20 mg/kg or 40 mg/kg; once daily; 7 w) reduces the growth of tumors in an ovarian cancer xenograft model[1]. |
| Animal Protocol |
6-week-old athymic nude mice injected with SKOV3 cells 20 mg/kg or 40 mg/kg Injection; 20 mg/kg or 40 mg/kg; once daily; 7 weeks |
| References |
[1]. Aloesin Suppresses Cell Growth and Metastasis in Ovarian Cancer SKOV3 Cells through the Inhibition of the MAPK Signaling Pathway. Anal Cell Pathol (Amst). 2017;2017:8158254. [2]. Aloesin from Aloe vera accelerates skin wound healing by modulating MAPK/Rho and Smad signaling pathways in vitro and in vivo. Phytomedicine. 2017 May 15;28:19-26. [3]. Aloesin and arbutin inhibit tyrosinase activity in a synergistic manner via a different action mechanism. Arch Pharm Res. 1999 Jun;22(3):232-6. |
| Additional Infomation |
Aloesin is a member of chromones. Aloesin has been reported in Aloe ferox, Aloe africana, and other organisms with data available. |
Solubility Data
| Solubility (In Vitro) | DMSO: 78~270 mg/mL (197./~684.6 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.25 mg/mL (5.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.25 mg/mL (5.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.25 mg/mL (5.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5357 mL | 12.6784 mL | 25.3569 mL | |
| 5 mM | 0.5071 mL | 2.5357 mL | 5.0714 mL | |
| 10 mM | 0.2536 mL | 1.2678 mL | 2.5357 mL |